Portola, Bristol-Myers Squibb and Pfizer sign clinical collaboration agreement to study ELIQUIS® and Portola's universal Factor Xa inhibitor antidote PRT4445
- Details
- Category: Bristol-Myers Squibb
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS® (apixaban).
Boehringer Ingelheim presents robust pipeline highlighting its Respiratory R&D
- Details
- Category: Boehringer Ingelheim
At its 3rd International Research & Development press conference, Boehringer Ingelheim unveiled a pipeline of unique asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer compounds that builds on the company's vast respiratory experience over many decades.
Novartis to start construction of new biotechnology facility in Singapore
- Details
- Category: Novartis
Novartis announced the construction of a new state-of-the-art biotechnology production site in Singapore with an investment valued at over USD 500 million. The new facility will focus on drug substance manufacturing based on cell culture technology. It will be co-located with the pharmaceutical production site based in Tuas, Singapore.
Bayer on track for a successful 2012
- Details
- Category: Bayer
The Bayer Group remains on a path of growth. Sales of the Bayer Group advanced by 11.5 percent in the third quarter, to EUR 9,665 million (Q3 2011: EUR 8,670 million). The currency- and portfolio-adjusted increase was 5.5 percent. Earnings before interest and taxes (EBIT) fell by 23.7 percent to EUR 838 million (Q3 2011: EUR 1,099 million).
GSK announces start of Phase lll programme for mepolizumab in severe refractory asthma
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) has announced the start of a Phase III programme to evaluate the efficacy and safety of mepolizumab, an investigational IL-5 antagonist, as adjunctive therapy in severe uncontrolled refractory asthma. The Phase III programme includes two key studies:
The Respimat® success story: Boehringer Ingelheim doubles its production capacity
- Details
- Category: Boehringer Ingelheim
Successful treatment of respiratory diseases also depends on how much of the active substance enters the patient's lung. Boehringer Ingelheim's Respimat® Soft Inhaler and its long-lasting aerosol cloud effectively transport the active substance into the lung.
Recently launched products support Novartis sales in third quarter
- Details
- Category: Novartis
Novartis net sales reached USD 13.8 billion in the third quarter. Currency had a negative impact of 5 percentage points as a result of the strengthening of the dollar against most major currencies. As the Group begins to face generic competition to Diovan in the US, the continuing rejuvenation of the portfolio leaves Novartis well-positioned. Products launched since 2007, which include Lucentis, Gilenya, Afinitor and Tasigna, continued to perform strongly.
More Pharma News ...
- Bristol-Myers Squibb reports third quarter 2012 financial results
- AstraZeneca and Ironwood announce linaclotide collaboration for China
- Abbott announces three-year long-term data evaluating efficacy with HUMIRA® (Adalimumab)
- Abbott reports double digit earnings per share growth in the third quarter
- YERVOY® (ipilimumab) awarded prestigious Prix Galien USA 2012 for best biotechnology product
- Roche Group posts strong sales growth in the third quarter
- Boehringer Ingelheim congratulates Nobel Prize winner Prof. Brian Kobilka